Corcept Therapeutics Incorporated
CORTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Corcept Therapeutics Incorporated focuses on Biotechnology services and products. Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders. The $12.07B market capitalization puts CORT squarely in large-cap range for its industry. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Market Cap
$12.07B
Beta
0.45
P/E (TTM)
248.04
P/E (Fwd)
25.35
EPS (TTM)
$0.45
EPS (Fwd)
$4.40
ROE
8.2%
ROA
0.5%
Cash
$308.2M
Total Debt
$9.4M
Free CF
$77.4M
52W Change
58.4%
Annual Financials
Cash vs Debt
Where CORT stands vs its 150-day and 200-day moving averages
As of the August 31, 2026 close, CORT finished 73.47% above its 150-day moving average ($65.65) and 72.75% above its 200-day moving average ($65.92). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CORT overbought or oversold?
At the August 31, 2026 close, CORT's RSI(14) was 49.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $308.2M in cash comfortably exceeding the $9.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $77.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 8.2% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 0.5% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $401.9M (2022) to $761.4M (2025), reflecting a 89% increase over the period.
CORT's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Corcept Therapeutics Incorporated and its sector.